Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Tue, August 11, 2026 at 8:30 PM GMT+3 3 min read

XTNT -27.13%

Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Reported revenue faced significant year-over-year headwinds due to the divestiture of non-core assets to Companion Spine and the cessation of certain license revenue following reimbursement changes.
The integration of 17 new sales representatives from the Dilon distribution agreement consumed significant management resources, contributing to softer-than-expected Q2 sales performance.
Management attributed biologics underperformance to softness in legacy 'workhorse' product lines and ongoing headwinds in the amniotic membrane market tied to advanced wound care.
The launch of Trivium Shaped in May is driving early sales momentum by addressing surgeon needs for pre-shaped configurations that reduce preparation time and improve consistency.
The company is transitioning from a small commercial footprint to a scaled organization with over 25 reps and expanded national accounts teams to drive institutional adoption.
Strategic entry into the $1 billion hemostasis market via HEMOBLAST Bellows provides access to high-value hospital systems like Cleveland Clinic and Mass General.

Outlook and Strategic Assumptions

Full-year 2026 revenue guidance was modestly reduced to $99 million to $103 million, reflecting Q2 biologics softness and persistent amnio product headwinds.
Management expects accelerating biologics growth in Q3 and beyond as the newly integrated specialty reps move past the learning curve and begin selling the full product bag.
Substantially all HEMOBLAST Bellows sales are expected to transition to Xtant's own customer agreements, allowing for gross revenue recognition versus the net basis used in Q2.
The company anticipates significant sales synergies as legacy reps and new specialty reps share few overlapping call points, allowing for broader market penetration.
Future growth strategy relies on leveraging a broad regenerative medicine portfolio to become a 'one-stop shop' for hospital materials management and large practice groups.

Operational and Financial Context

A $5 million exclusivity fee paid to Dilon Technologies was recorded as a one-time operating expense in the second quarter.
Gross margin declined to 57.9% primarily due to the termination of Q-Code license revenue and reduced production efficiencies.
Revenue recognition for HEMOBLAST was approximately $600,000 to $700,000 lower than potential due to the timing of transitioning purchase orders from Dilon to Xtant.
Cash and cash equivalents decreased to $9.9 million as of June 30, 2026, compared to $17.3 million at the end of 2025.

Q&A Session Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Specific drivers of orthobiologics underperformance relative to initial expectations

Management identified 'old line' products like OsteoSelect and OsteoSponge as being down more than anticipated.
The Amnio product line remains soft, and while 'green shoots' were expected, the recovery has not yet materialized as planned.

Cross-selling opportunities and synergies from the Dilon sales force

The new reps provide entry into non-orthobiologic areas like OB/GYN where products like CollagenX and Amnio have strong applications.
The 17 new reps will be tasked with managing approximately 400 'transactional' independent agent accounts that previously lacked consistent coverage.
Management believes the new team's relationships with hospital materials management will facilitate larger institutional contracts.

HEMOBLAST revenue recognition and transactional volume expectations

Management maintains an expectation of over $1 million per month in gross transactional volume for HEMOBLAST.
A 'buffer' remains in Q3 guidance to account for any remaining orders that might still be processed through Dilon during the final stages of the contract transition.